Association of Impaired Glucose Metabolism in Morbid Obesity with Hypoadiponectinaemia

Abstract

Background: Increased circulating levels of cytokines and chemokines and decreased adiponectin levels are associated with impaired glucose tolerance (IGT) and type 2 diabetes mellitus (T2DM). As obesity is the major risk factor for T2DM it is not clear why many patients with morbid obesity remain normoglycaemic and if this protection can be attributed to a lower grade of inflammation or higher adiponectin levels.

Materials and methods: Glucose tolerance of morbidly obese patients (n=2 754, body mass index ≥40 kg/m²) was assessed by oral glucose tolerance tests. In a case-control design we compared levels of eight immune mediators and adiponectin from patients with IGT/T2DM (n=52) and normal glucose tolerance (NGT; n=59). Gene expression in peripheral blood was determined by quantitative RT-PCR, and serum concentrations of immune mediators and adiponectin were measured by ELISA and bead-based multiplex technology.

Results: About 54% of the patients in our morbidly obese cohort were normoglycaemic, while 14% were diagnosed with IGT and 32% with T2DM. There was no statistically significant difference in mRNA expression or serum levels of proinflammatory markers. Interestingly, we could demonstrate an association of NGT with higher adiponectin levels (p=0.039). Adiponectin levels were negatively correlated with interleukin (IL)-6 and macrophage chemoattractant protein (MCP)-1, but independent the other immune mediators.

Conclusions: We found an association of lower adiponectin levels with IGT/T2DM, but no further increase in inflammatory markers in morbid obesity. This suggests that in addition to chronic, low-grade inflammation, adiponectin is an important factor in the development of, or protection against, T2DM in obesity.

adiponectin - inflammation - obesity - diabetes mellitus - peripheral blood

References

• 1 Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome.  Lancet. 2005;  365 1415-1428
• 2 Schinner S, Scherbaum WA, Bornstein SR, Barthel A. Molecular mechanisms of insulin resistance.  Diabet Med. 2005;  22 674-682
• 3 Kopelman PG. Obesity as a medical problem.  Nature. 2000;  404 635-643
• 4 Hensrud DD, Klein S. Extreme obesity: a new medical crisis in the United States.  Mayo Clin Proc. 2006;  81 S5-S10
• 5 Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women.  Ann Intern Med. 1995;  122 481-486
• 6 Kempf K, Rose B, Herder C, Haastert B, Fusbahn-Laufenburg A, Reifferscheid A. et al . The metabolic syndrome sensitizes leukocytes for glucose-induced immune gene expression.  J Mol Med. 2007;  85 389-396
• 7 Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes.  Trends Immunol. 2004;  25 4-7
• 8 Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes?.  Diabetologia. 2005;  48 1038-1050
• 9 Cipolletta C, Ryan KE, Hanna EV, Trimble ER. Activation of peri-pheral blood CD14+monocytes occurs in diabetes.  Diabetes. 2005;  54 2779-2786
• 10 Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion.  J Clin Endocrinol Metab. 2007;  92 1023-1033
• 11 Weisberg SP, MacCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr AW. Obesity is associated with macrophage accumulation in adipose tissue.  J Clin Invest. 2003;  112 1796-1808
• 12 Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ. et al . Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.  J Clin Invest. 2003;  112 1821-1830
• 13 Curat CA, Miranville A, Sengenes C, Diehl M, Tonus C, Busse R. et al . From blood monocytes to adipose tissue-resident macrophages: induc-tion of diapedesis by human mature adipocytes.  Diabetes. 2004;  53 1285-1292
• 14 Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS. et al . Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo.  J Clin Endocrinol Metab. 1997;  82 4196-4200
• 15 Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity.  J Clin Endocrinol Metab. 1997;  82 1313-1316
• 16 Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion.  Obes Res. 2001;  9 414-417
• 17 Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B. et al . Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors.  Diabetologia. 2002;  45 805-812
• 18 Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus.  JAMA. 2001;  286 327-334
• 19 Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE. et al . The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study.  Diabetes. 2001;  50 2384-2389
• 20 Thorand B, Baumert J, Kolb H, Meisinger C, Chambless L, Koenig W. et al . Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002.  Diabetes Care. 2007;  30 854-860
• 21 Esposito K, Pontillo A, Palo C Di, Giugliano G, Masella M, Marfella R. et al . Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial.  JAMA. 2003;  289 1799-1804
• 22 Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M. et al . Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year.  Circulation. 2002;  105 804-809
• 23 Yener S, Demir T, Akinci B, Bayraktar F, Kebapcilar L, Ozcan MA. et al . Transforming growth factor-beta 1 levels in women with prior history of gestational diabetes mellitus.  Diabetes Res Clin Pract. 2007;  76 193-198
• 24 Kim CS, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE. et al . Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters.  Int J Obes (Lond). 2006;  30 1347-1355
• 25 Maury E, Ehala-Aleksejev K, Guiot Y, Detry R, Vandenhooft A, Brichard SM. Adipokines oversecreted by omental adipose tissue in human obesity.  Am J Physiol Endocrinol Metab. 2007;  293 E656-E665
• 26 Herder C, Schneitler S, Rathmann W, Haastert B, Schneitler H, Winkler H. et al . Low-grade inflammation, obesity and insulin resistance in adolescents.  J Clin Endocrinol Metab. 2007;  92 4569-5474
• 27 Herder C, Haastert B, Muller-Scholze S, Koenig W, Thorand B, Holle R. et al . Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4).  Diabetes. 2005;  54 S11-S17
• 28 Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state.  Circulation. 2004;  110 1564-1571
• 29 Fogelstrand L, Hulthe J, Hulten LM, Wiklund O, Fagerberg B. Monocytic expression of CD14 and CD18, circulating adhesion molecules and inflammatory markers in women with diabetes mellitus and impaired glucose tolerance.  Diabetologia. 2004;  47 1948-1952
• 30 Sell H, Eckel J, Dietze-Schroeder D. Pathways leading to muscle insulin resistance – the muscle – fat connection.  Arch Physiol Biochem. 2006;  112 105-113
• 31 Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease.  Endocr Rev. 2006;  27 762-778
• 32 Fasshauer M, Paschke R, Stumvoll M. Adiponectin, obesity, and cardiovascular disease.  Biochimie. 2004;  86 779-784
• 33 Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE. et al . Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.  J Clin Endocrinol Metab. 2001;  86 1930-1935
• 34 Kempf K, Hector J, Strate T, Schwarzloh B, Rose B, Herder C. et al . Immune-mediated activation of the endocannabinoid system in visceral adipose tissue in obesity.  Horm Metab Res. 2007;  39 595-600
• 35 Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ.  Diabetes. 2006;  55 1537-1545
• 36 Herder C, Hauner H, Haastert B, Rohrig K, Koenig W, Kolb H. et al . Hypoadiponectinemia and proinflammatory state: two sides of the same coin?: results from the Cooperative Health Research in the Region of Augsburg Survey 4 (KORA S4).  Diabetes Care. 2006;  29 1626-1631
• 37 Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K. et al . PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein.  Diabetes. 2001;  50 2094-2099
• 38 Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K. et al . The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.  Nat Med. 2001;  7 941-946
• 39 Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30.  J Clin Invest. 2001;  108 1875-1881
• 40 Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S. et al . Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.  Nat Med. 2002;  8 1288-1295
• 41 American Diabetes Association. . Diagnosis and classification of diabetes mellitus.  Diabetes Care. 2006;  29 S43-S48
• 42 Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system?.  Diabetologia. 1998;  41 1241-1248
• 43 Herder C, Baumert J, Thorand B, Koenig W, Jager W de, Meisinger C. et al . Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002.  Diabetologia. 2006;  49 921-929
• 44 Herder C, Kolb H, Koenig W, Haastert B, Muller-Scholze S, Rathmann W. et al . Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg, Survey 4 (KORA S4).  Diabetes Care. 2006;  29 368-371
• 45 Herder C, Klopp N, Baumert J, Muller M, Khuseyinova N, Meisinger C. et al . Effect of macrophage migration inhibitory factor (MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: results from the MONICA/KORA Augsburg Case-Cohort Study, 1984-2002.  Diabetologia. 2008;  51 276-284
• 46 Rathmann W, Haastert B, Herder C, Hauner H, Koenig W, Meisinger C. et al . Differential association of adiponectin with cardiovascular risk markers in men and women. The KORA survey 2000.  Int J Obes (Lond). 2007;  31 770-776
• 47 Nugent C, Younossi ZM. Evaluation and management of obesity-related nonalcoholic fatty liver disease.  Nat Clin Pract Gastroenterol Hepatol. 2007;  4 432-441
• 48 Nannipieri M, Gonzales C, Baldi S, Posadas R, Williams K, Haffner SM. et al . Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study.  Diabetes Care. 2005;  28 1757-1762
• 49 Lee DH, Silventoinen K, Jacobs Jr DR, Jousilahti P, Tuomileto J. Gamma-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women.  J Clin Endocrinol Metab. 2004;  89 5410-5414
• 50 Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y. et al . Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin.  Circulation. 1999;  100 2473-2476
• 51 Huth C, Heid IM, Vollmert C, Gieger C, Grallert H, Wolford JK. et al . IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies.  Diabetes. 2006;  55 2915-2921
• 52 Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent?.  Diabetes. 2005;  54 ((Suppl 2)) S114-S124
• 53 Sell H, Dietze-Schroeder D, Kaiser U, Eckel J. Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle.  Endocrinology. 2006;  147 2458-2467
• 54 Sell H, Kaiser U, Eckel J. Expression of chemokine receptors in insulin-resistant human skeletal muscle cells.  Horm Metab Res. 2007;  39 244-249

1 These authors contributed equally to the work.

Correspondence